SK Life Science gets FDA OK for Xcopri
SK Life Science has received the Food and Drug Administration’s clearance for Xcopri (cenobamate tablets) to treat partial-onset seizures in adults.
“Xcopri is a new option to treat adults with partial-onset seizures, which is an often difficult-to-control condition that can have a significant impact on patient quality of life,” said Billy Dunn, director of the office of neuroscience in the FDA’s center for drug evaluation and research. “Patients can have different responses to the various seizure medicines that are available. This approval provides an additional needed treatment option for people with this condition.”